.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Covington
Express Scripts
US Department of Justice
Chubb
Chinese Patent Office
Medtronic
US Army
Cerilliant
McKinsey

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,546,379

« Back to Dashboard

Which drugs does patent 8,546,379 protect, and when does it expire?


Patent 8,546,379 protects BELVIQ XR and BELVIQ and is included in two NDAs. There have been zero Paragraph IV challenges on Belviq XR and Belviq

This patent has fifty-five patent family members in twenty-eight countries.

Summary for Patent: 8,546,379

Title:5HT.sub.2C receptor modulators
Abstract: The present invention relates to novel compounds of Formula (I): ##STR00001## which act as 5HT.sub.2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
Inventor(s): Smith; Brian (San Diego, CA), Smith; Jeffrey (San Diego, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:13/617,072
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eisai IncBELVIQ XRlorcaserin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes► Subscribe► SubscribeYYMETHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY► Subscribe
Eisai IncBELVIQ XRlorcaserin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes► Subscribe► SubscribeYYMETHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY► Subscribe
Eisai IncBELVIQ XRlorcaserin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes► Subscribe► SubscribeYYMETHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN► Subscribe
Eisai IncBELVIQ XRlorcaserin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes► Subscribe► SubscribeYYMETHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE► Subscribe
Eisai IncBELVIQlorcaserin hydrochlorideTABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► SubscribeYYMETHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY► Subscribe
Eisai IncBELVIQlorcaserin hydrochlorideTABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► SubscribeYYMETHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY► Subscribe
Eisai IncBELVIQlorcaserin hydrochlorideTABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► SubscribeYYMETHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN► Subscribe
Eisai IncBELVIQlorcaserin hydrochlorideTABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► SubscribeYYMETHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,546,379

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,846,9065HT.sub.2C receptor modulators► Subscribe
6,953,787 5HT2C receptor modulators► Subscribe
8,993,7505HT.sub.2C receptor modulators► Subscribe
8,575,1495HT2C receptor modulators► Subscribe
8,207,1585HT2c receptor modulators► Subscribe
8,273,7345HT.sub.2C receptor modulators► Subscribe
7,977,3295HT.sub.2C receptor modulators► Subscribe
7,514,4225HT.sub.2c receptor modulators► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,546,379

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine77788► Subscribe
TaiwanI252105► Subscribe
Taiwan200400037► Subscribe
Slovenia1411881► Subscribe
Russian Federation2317982► Subscribe
Russian Federation2004133068► Subscribe
Portugal1411881► Subscribe
Poland396873► Subscribe
Poland219017► Subscribe
Poland211333► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Farmers Insurance
US Army
Fuji
Healthtrust
AstraZeneca
Harvard Business School
Accenture
Cerilliant
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot